Golexin (Goserelin)

Golexin is indicated for several hormone‑sensitive conditions where suppression of sex steroids is desired.

• Prostate cancer in men, typically combined with anti‑androgen agents as part of androgen deprivation therapy to lower testosterone levels.
• Hormone‑receptor positive breast cancer in pre‑menopausal women, employed to achieve ovarian suppression before or during chemotherapy or endocrine therapy.
• Endometriosis, where reduction of estrogen production helps alleviate pelvic pain, dysmenorrhea, and lesion progression.
• Uterine fibroids, used to shrink fibroid volume, reduce menorrhagia, and potentially avoid surgical intervention.
• Central precocious puberty, administered to delay the onset of secondary sexual characteristics by suppressing gonadotropin release.

The safety profile of Golexin reflects the pharmacologic impact of GnRH agonism on hormone levels and injection site reactions.

Common

• Mild to moderate injection site pain, erythema, induration, or swelling that usually resolves within days.
• Transient hot flashes and sweating, often occurring during the initial weeks of therapy.
• Reduced libido, erectile dysfunction, or decreased sexual interest, particularly in male patients.
• Irregular menstrual bleeding, amenorrhea, or changes in cycle length in female patients.

Serious

• Severe allergic reactions such as anaphylaxis, angioedema, or urticaria requiring immediate medical attention.
• Significant loss of bone mineral density, increasing the risk of osteoporosis and fractures with prolonged therapy.
• Rare cardiovascular complications, including thromboembolic events or myocardial infarction, especially in patients with pre‑existing risk factors.

Before initiating Golexin, clinicians should evaluate several precautionary factors to ensure safe use.

• Pregnancy contraindication: Golexin is classified as pregnancy category X and must not be used in pregnant women.
• Fertility considerations: Treatment can cause temporary or permanent infertility; discuss reproductive plans with patients.
• Bone health monitoring: Long‑term therapy may reduce bone mineral density; consider baseline DEXA scans and calcium/vitamin D supplementation.
• Cardiovascular risk: Assess history of thromboembolic disease or coronary artery disease before use.
• Hormone‑dependent tumor monitoring: Regularly evaluate disease status, as hormone suppression can affect tumor markers.

Golexin may interact with other medicines that influence hormone levels, liver metabolism, or immune response.

Avoid

• Avoid using other GnRH agonists or antagonists together, as this can cause excessive gonadotropin suppression and severe hypo‑gonadism.
• Avoid strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) because they may lower goserelin levels and reduce efficacy.

Use with caution

• Use with caution with anticoagulants (warfarin, DOACs) since hormonal changes can affect coagulation and bleeding risk.
• Use with caution alongside bisphosphonates or denosumab; monitor bone density regularly to detect additive bone loss.
• Use with caution when combined with chemotherapy, as overlapping myelosuppression may increase neutropenia or anemia; adjust schedules as needed.